-

AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel

ROTTERDAM, Netherlands--(BUSINESS WIRE)--AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities.

According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capabilities around “end-to-end” supply chain needs. “AIM is well known as a leader in supply chain development for launch, as well as optimization of existing supply chains — supporting clients in getting their finished products to patients,” said Mr. de Bakker. “We are now adding new capabilities in supply chain diagnostics and strategy, end-to-end planning optimization, supply reliability, and working capital optimization, among others. Combined with AIM’s established supply chain expertise, this expanded offering gives clients true ‘end-to-end’ support, from source to patient.”

Mr. de Bakker added, “What Thomas brings in end-to-end supply chain strategy and optimization complements what AIM already does exceptionally well. We’re delighted to have him on board.” Mr. Ebel will play a key role in expanding AIM’s capabilities and is expected to grow the team by recruiting additional specialists in the months ahead.

“I was attracted to AIM by a rare combination,” said Mr. Ebel. “Genuine deep expertise in life science supply chain and distribution, a hands-on pragmatic approach, and a team of consultants who have actually done the work. The track record speaks for itself, and I’m excited to get started. In these times, life science companies need to move from defense to offense and build stronger supply chains that are both integrated with the business and adaptable to change. This is where we will focus.”

About AIM

AIM (www.aimconnection.eu), a Blue Matter company, is the trusted supply chain specialist for life science companies. From its offices in the Netherlands, AIM provides end-to-end supply chain services and support across the globe. It helps a broad range of pharmaceutical and biotech companies strategically design, build, implement, and maintain their operational and supply chain infrastructures. AIM supports companies at every stage, from emerging clinical-stage innovators preparing for their first product launch to large established global organizations optimizing complex supply chains.

Contacts

Craig Dunkley
cdunkley@bluematterconsulting.com
(919) 539-0658

More News From AIM

Blue Matter Launches People and Organization Practice to Help Biopharma Navigate Structural Shift

NEW YORK--(BUSINESS WIRE)--Blue Matter today announced the launch of its People and Organization Practice, a dedicated capability designed to help life science companies build organizations that can perform through complexity - from enterprise transformation and M&A integration to talent strategy, learning, and workforce redesign. The launch reflects a central conviction: the biopharma industry is not experiencing a cyclical downturn but a structural shift. With more than 42,700 jobs cut ac...

Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik

NEW YORK--(BUSINESS WIRE)--Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optim...

Blue Matter Enhances Twine™ Platform Capabilities in Response to Growing Demand

SAN FRANCISCO--(BUSINESS WIRE)--Blue Matter today announced the expansion of its Twine™ data platform’s capabilities in response to accelerating demand from biopharma companies. Enhancements include thoughtful use of artificial intelligence (AI) for advanced analytics and narratives, expanded data source integrations, master data management, and broader deployment across oncology and specialty therapeutic areas. Twine™ is Blue Matter's purpose-built customer intelligence platform for healthcare...
Back to Newsroom